



## COMBINATORIAL BIOLOGY TECHNOLOGY

BEST AVAILABLE COPY

Neugenesis' combinatorial biology technology (the CombiKARYON™ system) mimics the immune system's ability to generate diversity in antibodies, and expands the application to all heteromeric proteins. The company uses this technology to discover and improve complex proteins. It is an efficient and cost-effective method to improve a protein's stability, affinity, receptor binding capacity, and therapeutic efficacy, thereby enhancing the value of the protein, and decreasing the risk of clinical failure.

### Using Combinatorial Biology to Generate Diversity

An outgrowth of Neugenesis' protein production systems, CombiKARYON™ uses the unique features of the filamentous fungus, *Neurospora crassa*, to create combinatorial panels of heavy and light chains of a heteromeric protein and to build libraries of diverse, new, fully assembled proteins. Variants of each subunit gene are generated within the host by Neugenesis' proprietary technology. Strains carrying these new gene sequences are fused to one another in all possible combinations to produce libraries in the following manner.

VARIANT	Light chain 1	Light chain 2	Light chain 3	Light chain 4
Heavy chain 1	L1H1	L2H1	L3H1	L4H1
Heavy chain 2	L1H2	L2H2	L3H2	L4H2
Heavy chain 3	L1H3	L2H3	L3H3	L4H3
Heavy chain 4	L1H4	L2H4	L3H4	L4H4

In this illustration, 16 unique monoclonal antibody combinations are produced from 4 light and 4 heavy chain subunit variants. In a standard microtiter plate configuration, 96 unique combinations would be produced when 12 variants of one subunit are arrayed against 8 variants of the second subunit. With CombiKARYON™, this would be done with 20 total transformations. Traditional protein engineering techniques would require 96 transformations after a complicated reassembly process of the subunit genes. These burdensome steps are eliminated using Neugenesis' combinatorial biology approach. The advantages become more apparent in larger libraries. For example, a 100x100

BEST AVAILABLE COPY

matrix to create 10,000 combinations would require 200 transformations in the CombiKARYON™ system, and 10,000 transformations using traditional techniques. This technology can also be used to create combinations of more than two subunits, to geometrically increase the diversity. The last step is to screen the combinatorial libraries for new proteins with the desired characteristics.

## Applying Combinatorial Biology to Drug Discovery and Improvement

CombiKARYON™ is an expedient approach for companies involved in developing difficult and complex protein therapeutics. The applications of the technology are numerous. For example, Neogenesis' technology may be applied to protein hits to improve the characteristics such as binding capacity or stability. By designing and creating small changes in the original molecule, Neogenesis is able to fine-tune the protein without dramatically changing the protein's core structure, which has already been selected for through years of evolution. This technology can also be applied to protein drug candidates already in pre-clinical and clinical trials. The failure rate of drug candidates in the development process is estimated to be at least 60-80%. Neogenesis' combinatorial biology system may help by providing a means to more efficiently fine-tune these candidates into better, therapeutically useful molecules.

Other potential applications of CombiKARYON™ include drug combination research and hybridization. In drug combination research, combinatorial biology enables rapid and inexpensive creation of any number of combinations of synergistic proteins, which can then be screened for the most effective combination. In hybridization, combinatorial biology can be used to develop hybrid molecules with both binding and effector moieties, improving the specificity of therapeutic agents.

In addition, cultures of desirable molecules identified through this technology can be easily expanded to produce large-scale quantities of the new heteromeric protein for further evaluation, since the protein is already in a *Neurospora* production strain.

---

<a href="#"><u>Protein Expression</u></a>	<a href="#"><u>Neogenesis' Homepage</u></a>	<a href="#"><u>Company Overview</u></a>	<a href="#"><u>Neogenesis in the News</u></a>	<a href="#"><u>Technology Tour</u></a>
---	---	---	---	--

---

**Neogenesis Corporation**  
**871 Industrial Road, Suite J**  
**San Carlos, California 94070**

Tel. 650-508-9672

[info@neogenesis.com](mailto:info@neogenesis.com)

Fax. 650-508-9171